Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 89-95

  Kim, Sun Young ^a   Kim, Hwang Phill ^a   Kim, Yu Jung ^a   Oh, Do Youn ^a   Im, Seock Ah ^a   Lee, Dongsoon ^a   Jong, Hyun Soon ^a   Kim, Tae You ^a   Bang, Yung Jue ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cisplatin; Drug synergism; HER2; p27; Stomach neoplasms

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PROTEIN KINASE B; STAT3 PROTEIN; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 38749149510     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.89     Document Type: Article

References (23)

1. Pegram MD, Lopez A, Konecny G and Slamon DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27: 21-25, 2000.
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
3. Nakajima M, Sawada H, Yamada Y, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
4. Orita H, Maehara Y, Emi Y, Kakeji Y, Baba H, Korenaga D and Sugimachi K: c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology 44: 294-298, 1997.
5. Im SA, Lee KE, Nam EM, et al: The prognostic significance of the overexpression of HER-2/neu in Korean gastric carcinomas and the in vitro effects of anti-HER-2/neu antibody on cell growth in the gastric carcinoma cell lines. Cancer Res Treat 35: 109-116, 2003.
6. Ku JL and Park JG: Biology of SNU cell lines. Cancer Res Treat 37: 1-19, 2005.
7. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
8. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141, 2002.
9. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapychemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
10. Kim JH, Lee KW, Jung Y, et al: Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 96: 365-371, 2005.
11. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N and Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Onco127: 681-685, 2005.
12. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K and Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59: 795-805, 2007.
13. Normanno N, Campiglio M, De Luca A, et al: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72, 2002.
14. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast rumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172, 1989.
15. Le XF, Pruefer F and Bast RC Jr: HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kipl via multiple signaling pathways. Cell Cycle 4: 87-95, 2005.
16. Waug CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT and Digiovanna MP: In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat 92: 251-263, 2005.
17. Zhou BP and Hung MC: Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 30: 38-48, 2003.
18. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF and Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895, 2001.
19. Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
20. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB and Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829-1838, 1994.
21. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R and Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739-749, 2004.
22. Cvitkovic E: Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77 (suppl 4): 8-11, 1998.
23. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999.